The Medicines Company to Host Investor Conference Call and Webcast During National Lipid Association's 2019 Scientific Sessions

• Company management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from ongoing ORION-3 study

The Medicines Company MDCO will host a conference call and webcast for investors on Saturday, May 18, 2019, at 5:30 p.m. EDT. During the call, the Company's management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from the ongoing ORION-3 study. The data will be presented during the late-breaking clinical trial session earlier the same day at the National Lipid Association (NLA) 2019 Scientific Sessions in Miami.

Inclisiran, the first cholesterol-lowering therapy in the small interfering RNA (siRNA) class, is the only medicine in late-stage clinical development with the potential to deliver potent, durable and consistent lowering of LDL cholesterol through twice-a-year dosing.

ORION-3 is an open-label Phase 2, extension study (of ORION-1) to assess the efficacy, safety and tolerability of long-term dosing of inclisiran. The study also evaluates safety and efficacy of switching patients treated with evolocumab to inclisiran. Follow up for this latter group is still ongoing and will be presented at a later date.

Conference Call

The conference call may be accessed as follows:

U.S./Canada: (877) 407-0312

International: (201) 389-0899

Conference ID: 13690839

The slide deck and live webcast may be accessed in the Investors section of The Medicines Company website.

A taped replay of the conference call will be available for approximately one month. The replay may be accessed as follows:

U.S./Canada: (877) 660-6853

International: (201) 612-7415

Conference ID: 13690839

A replay of the webcast will also be available in the Investors section of The Medicines Company website.

About The Medicines Company

The Medicines Company is a biopharmaceutical company whose purpose is to halt the deadly progression of atherosclerosis and the cardiovascular risk created by high levels of LDL-C, or bad cholesterol. Our team is focused on transformational solutions that address the daily challenges that patients, physicians and payers confront in cardiovascular care. The Company is headquartered in Parsippany, New Jersey. For more information, please visit www.themedicinescompany.com and follow us on Twitter @MDCONews and LinkedIn.

About Inclisiran

Inclisiran is a small interfering RNA (siRNA) therapy being studied to evaluate its ability to lower low-density lipoprotein (LDL) cholesterol – also known as LDL-C or bad cholesterol. Inclisiran is designed to prevent the production of proprotein convertase subtilisin/kexin type 9 (PCSK9) at its source in the liver. Inclisiran is not yet approved for use by the FDA or any other regulatory authority. The Medicines Company obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement with Alnylam Pharmaceuticals.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190510005011/en/